Solriamfetol hydrochloride
Cat. No.: DC11529
Featured
Chemical Structure
178429-62-4
We are official vendor of:
More than 5000 active chemicals with high quality for research!
Field of application
Solriamfetol hydrochloride (JZP-110, R-228060, ADX-N05, YKP-10A) is a norepinephrine-dopamine reuptake inhibitor that inhibits dopamine and norepinephrine transporter with IC50 of 2.9 and 4.4 uM, respectively.
| Cas No.: |
178429-62-4 |
| Chemical Name: |
Solriamfetol |
| Synonyms: |
Solriamfetol hydrochloride;Solriamfetol (hydrochloride);K7RO88SP7A;Solriamfetol hydrochloride [USAN];Solriamfetol hydrochloride (USAN);Sunosi (TN);KAOVAAHCFNYXNJ-SBSPUUFOSA-N;SB19103;O-Carbamoyl-(D)-phenylalaninol hydrochloride;D11328;(betaR)-beta-amino-Benzenepropanol 1-carbamate hydrochloride (1:1);JZP-110 hydrochloride |
| SMILES: |
Cl.O(C(N)=O)C[C@@H](CC1C=CC=CC=1)N |
| Formula: |
C10H15ClN2O2 |
| M.Wt: |
230.691301584244 |
| Purity: |
>98% |
| Sotrage: |
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: |
Solriamfetol (JZP-110) is a selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects. Solriamfetol binds to dopamine and norepinephrine transporters, so it can inhibit reuptake of dopamine and norepinephrine. Solriamfetol treatment significantly improves the ability to stay awake and subjective symptoms of excessive sleepiness in adults with narcolepsy. |
| References: |
[1]. Yang J, et al. Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy. Expert Rev Clin Pharmacol. 2019 Aug;12(8):723-728. |
MSDS
COA
| LOT NO. |
DOWNLOAD |
|
|
| 2018-0101 |
|
| 2018-0101 |
|
Get Quote
